FDA warned Xtreme Tools International after an inspection found manufacturing-rule failures for OTC topical drugs, including missing ingredient and batch testing.
What happened
FDA inspected Xtreme Tools International's drug manufacturing facility in Opa Locka, FL, from January 27 to 31, 2025, and reviewed the company's February 20, 2025 response to the inspection observations. FDA found the company made over-the-counter (OTC) topical drugs without identity testing of incoming components, without adequate testing of glycerin and propylene glycol for diethylene glycol (DEG) and ethylene glycol (EG), and without finished-product release or objectionable-microorganism testing. The letter also cites missing process validation and an inadequate quality unit; the company said it ceased all drug production at the facility.
What FDA found
The company used salicylic acid active ingredient and other components without testing each incoming lot's identity or verifying the supplier's test results at appropriate intervals, and did not show its water met the Purified Water USP monograph.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company did not adequately test each shipment and lot of glycerin and propylene glycol for identity, including the United States Pharmacopeia (USP) limit test for diethylene glycol (DEG) and ethylene glycol (EG).
21 CFR 211.84(d)(1) and 211.84(d)(2)The company did not test each finished batch for identity and strength of active ingredients or for objectionable microorganisms before release.
21 CFR 211.165(a) and 211.165(b)The company did not validate its manufacturing processes, qualify equipment, or document qualification and maintenance of its water system.
21 CFR 211.100(a)The quality control unit lacked procedures and authority to oversee batch release, investigations, change control, complaints, training, cleaning and maintenance, and stability testing.
21 CFR 211.22; 21 CFR 211.22(d); 21 CFR 211.67(b); 21 CFR 211.166(a)
What FDA wants
FDA tells the company to respond in writing within 15 working days with corrective actions and preventive measures, or explain any delay and give a completion schedule. It also says to notify FDA before resuming drug manufacturing and recommends a qualified consultant if it does.
Who should pay attention
- brands and retailers selling OTC topical scrubs made by this contract manufacturer
- companies with Xtreme Tools drug products still on the market within expiry
- cosmetic brands using this facility
This is a summary. Read the original letter on fda.gov.